Další formáty:
BibTeX
LaTeX
RIS
@article{1830786,
author = {Bedanova, H. and Horvath, V. and Ondrasek, J. and Krejčí, Jan and Dobšák, Petr and Nemec, P.},
article_location = {BRATISLAVA},
article_number = {5},
doi = {http://dx.doi.org/10.4149/BLL_2021_051},
keywords = {biguanide; heart graft; malignancy; diabetes mellitus; survival},
language = {eng},
issn = {0006-9248},
journal = {Bratislava Medical Journal - Bratislavské lekárske listy},
title = {Metformin therapy and risk of cancer in patients after heart transplantation},
url = {http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7195&category_id=171&option=com_virtuemart&vmcchk=1&Itemid=1},
volume = {122},
year = {2021}
}
TY - JOUR
ID - 1830786
AU - Bedanova, H. - Horvath, V. - Ondrasek, J. - Krejčí, Jan - Dobšák, Petr - Nemec, P.
PY - 2021
TI - Metformin therapy and risk of cancer in patients after heart transplantation
JF - Bratislava Medical Journal - Bratislavské lekárske listy
VL - 122
IS - 5
SP - 305-309
EP - 305-309
PB - Univerzita Komenského
SN - 00069248
KW - biguanide
KW - heart graft
KW - malignancy
KW - diabetes mellitus
KW - survival
UR - http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7195&category_id=171&option=com_virtuemart&vmcchk=1&Itemid=1
N2 - BACKGROUND: Diabetes mellitus (DM) and malignancy are recognized among the most common complications increasing mortality in patients after heart transplantation (HTx). Clinical trials have shown a higher risk for different types of tumours in diabetic patients. This risk is potentiated by immunosuppressive therapy in transplant patients. Biguanide metformin has been shown to exhibit anti-tumour activity and we tried to find out whether this effect is valid for heart transplant patients. METHODS: We retrospectively analysed a group of 497 patients, who undergone HTx in our centre between 1998 and 2019. The primary outcome was any malignancy during the 15-year follow-up period and patient's survival. RESULTS: Out of the 497 patients enrolled in the study, 279 (56 %) had diabetes and 52 (19 %) were treated with metformin. Fifteen-year survival in treated patients without malignancy was 93 %, the remainder for the DM patients was 56 %, with survival in non-DM patients being 74 %. Untreated diabetic patients had 4.7 times higher chance of malignancy than those on metformin (p = 0.01). Fifteen-year survival in metformin treated patients was 53 %, in other DM patients 44 %, and in non-DM patients 51 %. CONCLUSION: Our study showed a significantly lower incidence of malignancies in metformin-treated patients and slightly better overall survival (Tab. 2, Fig. 3, Ref. 19). Text in PDF www.elis.sk
ER -
BEDANOVA, H., V. HORVATH, J. ONDRASEK, Jan KREJČÍ, Petr DOBŠÁK a P. NEMEC. Metformin therapy and risk of cancer in patients after heart transplantation. \textit{Bratislava Medical Journal - Bratislavské lekárske listy}. BRATISLAVA: Univerzita Komenského, 2021, roč.~122, č.~5, s.~305-309. ISSN~0006-9248. Dostupné z: https://dx.doi.org/10.4149/BLL\_{}2021\_{}051.
|
